Skip to main content

Decode Posts Q2 Revenue Surge, Greater R&D Spending, and Widened Loss

NEW YORK, Aug. 14 - Decode genetics yesterday reported a surge in second-quarter total revenue and said that an increase in R&D spending caused the company's net loss to swell.


Total revenue for he period ended Jun 30 were $13.4 million, a 116-percent jump over the $6.2 million the company posted one year ago.


R&D spending in the quarter increased to $23.3 million from $16.3 million in the same quarter in 2001, in line with overall operating expenses, which grew to $29 million from $20 million in the second quarter 2001, Decode said.


As a result, the company recorded an increase in net losses in the quarter to $16.8 million, or $.32 per share, from $12.3 million, or $.28 per share, year over year.


Decode said it had roughly $121.4 million in cash and cash equivalents as of June 30.


Click here for more information.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.